Aptamer Group and BizCom announce collaboration for Optimer services in Japan-BizCom Japan Inc. and Aptamer Group Ltd have agreed a distribution and marketing
agreement for services and products of Optimer discovery and development -York, UK and Tokyo, Japan (XX, 2021) - Aptamer Group, Ltd. the developer of Optimer® binders toenable innovation in the life science industry, and BizCom Japan, Inc. a Japan-based trading andconsultancy company, today announce that they have entered into a distribution and marketing
agreement.
This agreement gives BizCom non-exclusive rights to market and sell Optimer discovery anddevelopment services in Japan.
The Optimer platform consists of three integrated discovery processes that together increase thepotential target range of Optimer binders. These nucleic acid-based affinity ligands offer fasterdiscovery, increased batch consistency and increased stability, to remove the need for freezers andlonger shelf live than protein-based alternatives, to deliver a range of advantages to scientists.
BizCom Japan, Inc. will use its extensive experience and sales and marketing expertise in Japan’s life
sciences space to market Aptamer Group’s services in the region.
Dr Arron Tolley, CEO of Aptamer Group said: “We are delighted that we have established this clear
route to market for Optimer discovery services in Japan, one of the largest pharma and medtech
markets, with BizCom Japan. This is an important market for Aptamer Group and BizCom Japan are anexcellent partner and are associated with well-known, established suppliers. They have an excellent
reputation for customer support and a wide network throughout Japan.”
Dr Hiroyasu Nakatani, Executive Managing Director of BizCom Japan said: “We are pleased todistribute custom Optimer services into the Japanese market. Optimers are unique affinity ligands
showing specific binding activity, stability and offering novel solutions to researchers that cannot beachieved with alternative ligands, such as antibodies. To offer increased support to the life sciencemarket, we are delighted to bring this new technology to scientists in Japan.”Enquiries:- Ends-

Aptamer Group
Jane McLeod (Content Marketing Manager) +44 (0)1904 567 790
jane.mcleod@aptamergroup.com
Alto Marketing (Scientific PR)
David Robinson +44(0)1489 557672

davidr@alto-marketing.com

Consilium Strategic Communications (Corporate PR)
Matthew Neal / Suki Virji / Lucy Featherstone +44(0)20 3709 5700
aptamergroup@consilium-comms.com

BizCom Japan

ir@bizcom.co.jp

Editor’s notes
About Aptamer Group
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new
approaches in therapeutics, diagnostics and research applications. The Company strives todeliver transformational solutions, that meet the needs of life science researchers and developers through theuse of its proprietary Optimer platform.
Optimer binders are nucleic acid affinity ligands that can function as an antibody alternative. Despite manywell-recognised problems with antibodies, the global antibody market is currently worth over $145Bn.
Optimer binders are engineered to address many of the issues found with alternative affinity molecules, suchas antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development
companies, and research institutes covering a range of targets and applications with the objective ofestablishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists andcollaborators are enabled to make faster, more informed decisions that support discovery and development
across the Life Sciences.
About BizCom Japan
BizCom Japan, Inc. is a trading and consulting company based in Tokyo, Japan. From its foundation in1996, it has been collaborating with various innovative companies in biotechnology, pharmaceutical,
diagnostic, cosmetic and medical device industries. In addition to providing research reagents,
services and equipment to the life science research market, BizCom Japan actively intermediates inand out-licensing of various cutting-edge technologies for its collaborators. Through strategic
alliances with its collaborators, the Company aims to extend its reach around the world. Moreinformation is available at www.bizcomjapan.co.jp